C. Dass and P. Choong, Zoledronic acid inhibits osteosarcoma growth in an orthotopic model, Molecular Cancer Therapeutics, vol.6, issue.12, pp.3263-70, 2007.
DOI : 10.1158/1535-7163.MCT-07-0546

K. Koto, N. Horie, and S. Kimura, Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model, Cancer Letters, vol.274, issue.2, pp.271-78, 2009.
DOI : 10.1016/j.canlet.2008.09.026

L. Deley, M. Guinebretière, J. Gentet, and J. , SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients, European Journal of Cancer, vol.43, issue.4, pp.752-61, 2007.
DOI : 10.1016/j.ejca.2006.10.023

H. Assi, G. Missenard, and P. Terrier, Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial, Current Oncology, vol.17, issue.6, pp.23-31, 2010.
DOI : 10.3747/co.v17i6.578

K. Lan and D. Demets, Discrete Sequential Boundaries for Clinical Trials, Biometrika, vol.70, issue.3, pp.659-63, 1983.
DOI : 10.2307/2336502

S. Smeland, J. Whelan, and S. Bielack, Event-free survival and overall survival in 2,253 patients with osteosarcoma registered to EURAMOS-1, Proc Am Soc Clin Oncol, vol.33, 2015.

M. Matos, U. Tannuri, and R. Guarniero, The effect of zoledronate during bone healing, Journal of Orthopaedics and Traumatology, vol.17, issue.10, pp.7-12, 2010.
DOI : 10.1016/j.biomaterials.2004.09.026

C. R. Powles and T. , Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, vol.386, pp.1353-61, 2015.

K. Zarogoulidis, E. Boutsikou, and P. Zarogoulidis, The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis, International Journal of Cancer, vol.19, issue.7, pp.1705-1714, 2009.
DOI : 10.1002/ijc.24470

X. Wang, X. Yan, and Y. Li, A meta-analysis of the antitumor eff ect and safety of bisphosphonates in the treatment of multiple myeloma

S. Ahn, S. Kim, H. Lee, S. Lee, and J. Jeong, Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors, Journal of Breast Cancer, vol.17, issue.4, pp.350-55, 2014.
DOI : 10.4048/jbc.2014.17.4.350

P. Meyers, J. Healey, and A. Chou, Addition of pamidronate to chemotherapy for the treatment of osteosarcoma, Cancer, vol.467, issue.suppl 2, pp.1736-1780, 2011.
DOI : 10.1007/s11999-009-0912-9

R. Goldsby, T. Fan, and D. Villaluna, Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children???s Oncology Group, European Journal of Cancer, vol.49, issue.10, pp.2384-91, 2013.
DOI : 10.1016/j.ejca.2013.03.018

W. Högler, F. Yap, D. Little, G. Ambler, M. Mcquade et al., Short-term safety assessment in the use of intravenous zoledronic acid in children, The Journal of Pediatrics, vol.145, issue.5, pp.701-705, 2004.
DOI : 10.1016/j.jpeds.2004.06.066

H. Russell, S. Groshen, and T. Ara, A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study, Pediatric Blood & Cancer, vol.78, issue.2, pp.275-82, 2011.
DOI : 10.1007/s002770050496

R. Coleman, D. Cameron, and D. Dodwell, Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial, The Lancet Oncology, vol.15, issue.9, pp.997-1006, 2014.
DOI : 10.1016/S1470-2045(14)70302-X

P. Ottewell, N. Wang, and H. Brown, Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo, Clinical Cancer Research, vol.20, issue.11, pp.2922-2954, 2014.
DOI : 10.1158/1078-0432.CCR-13-1246

L. Endo-munoz, A. Cumming, and D. Rickwood, Loss of Osteoclasts Contributes to Development of Osteosarcoma Pulmonary Metastases, Cancer Research, vol.70, issue.18, pp.7063-72, 2010.
DOI : 10.1158/0008-5472.CAN-09-4291

A. Labrinidis, S. Hay, V. Liapis, D. Findlay, and A. Evdokiou, Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks effi cacy against pulmonary metastases in a syngeneic rat model, Int J Cancer, vol.127, pp.345-54, 2010.

V. Kunzmann, E. Bauer, and M. Wilhelm, ??/?? T-Cell Stimulation by Pamidronate, New England Journal of Medicine, vol.340, issue.9, pp.737-775, 1999.
DOI : 10.1056/NEJM199903043400914

S. Junankar, G. Shay, and J. Jurczyluk, Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer, Cancer Discovery, vol.5, issue.1, pp.35-42, 2015.
DOI : 10.1158/2159-8290.CD-14-0621

E. Buddingh, M. Kuijjer, and R. Duim, Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents, Clinical Cancer Research, vol.17, issue.8, pp.2110-2129, 2011.
DOI : 10.1158/1078-0432.CCR-10-2047

T. Abe, T. Sato, S. Kokabu, N. Hori, Y. Shimamura et al., Zoledronic acid increases the circulating soluble RANKL level in mice, with a further increase in lymphocyte-derived soluble RANKL in zoledronic acid- and glucocorticoid-treated mice stimulated with bacterial lipopolysaccharide, Cytokine, vol.83, pp.1-7, 2016.
DOI : 10.1016/j.cyto.2016.03.012